Cardiovasc Intervent Radiol (2017) 40:1480 DOI 10.1007/s00270-017-1708-z LETTE R T O T HE EDI T OR Authors’ Reply: Letter to the Editor Regarding ‘‘Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular- Cholangiocarcinoma’’ 1 1 David S. Wang Daniel Y. Sze Received: 18 May 2017 / Accepted: 19 May 2017 / Published online: 26 May 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 We thank the authors for their thoughtful comments on our was achieved with radioembolization. Since there is no article ‘‘Yttrium-90 Radioembolization for Unre- known cure and no standard of care for unre- sectable Combined Hepatocellular-Cholangiocarcinoma’’ sectable cHCC-CC, it is likely that future research, even  and appreciate the opportunity to address their prospective work, will also be subject to these limitations. concerns. Lastly, we thank the authors for identifying the dis- We agree with the authors that other therapies received crepancy between Table 1 and Figure 2B. In our cohort, before and after radioembolization are a limitation of this three patients demonstrated macrovascular invasion. The study, as acknowledged and reviewed in the Discussion correct version of Figure 2B is updated in an erratum section of our paper. Moreover, many clinical studies, linked to the original article (doi:10.1007/s00270-017- including prospective randomized controlled trials, are 1701-6). subject to these confounders. Since there are no manage- Compliance with Ethical Standards ment guidelines for unresectable combined hepatocellular- cholangiocarcinoma (cHCC-CC), it is to be expected that Conﬂict of interest D. Sze is on the medical or scientiﬁc advisory cHCC-CC patients undergo a variety of therapies of boards for Boston Scientiﬁc, Inc., Koli Medical, Inc., RadiAction Medical, Inc.; is a consultant for Amgen, Inc., BTG International, unknown efﬁcacy. We detailed all other therapies for each Inc., EmbolX, Inc., W.L. Gore & Associates, Inc., and Viralytics, individual patient to provide readers the context necessary Inc.; receives institutional research support from Merit Medical, Inc., to interpret the reported outcomes data. Furthermore, in our and W. L. Gore, Inc.; and owns equity interest in Conﬂuent Medical, assessment of response to radioembolization, we mini- Inc., and Proteus Digital Health, Inc. mized the confounding effects of prior treatments, when applicable, by using the cross-sectional imaging study Reference which showed disease progression after prior treatments as the ‘‘baseline’’ imaging study. We also minimized the 1. Chan LS, Sze DY, Poultsides GA, Louie JD, Mohammed MAA, effects of subsequent treatments after radioembolization by Wang DS. Yttrium-90 radioembolization for unresectable com- reporting best hepatic imaging response, since patients who bined hepatocellular-cholangiocarcinoma. Cardiovasc Intervent underwent additional therapies mostly did so after disease Radiol. 2017. doi:10.1007/s00270-017-1648-7. progression occurred after stable disease or partial response & David S. Wang firstname.lastname@example.org Division of Interventional Radiology, Stanford University School of Medicine, 300 Pasteur Drive, H3630, Stanford, CA 94305-5642, USA
CardioVascular and Interventional Radiology – Springer Journals
Published: May 26, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera